Wegovy

News

Novo Nordisk claims first GLP-1 approval in MASH

Under pressure from rivals in the GLP-1 space, Novo Nordisk has been given a leg-up with a first-in-class approval for Wegovy in liver disease MASH.

News

Novo Nordisk weakens again on interim results readout

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the first half of this year.

News

Noom Med app and accompanying GLP-1 implements

Noom expands its GLP-1 range with 'microdose' package

Noom is offering 'microdoses' of semaglutide at a knock-down price, claiming they can prevent side effects but remain effective for weight loss.

News

Novo Nordisk slumps as it cuts sales forecast, names new CEO

Novo Nordisk has a new CEO, facing an uphill battle to restore the fortunes of its US business as diabetes and obesity drugs come under pressure.

News

Novo Nordisk files high-dose Wegovy in EU

Novo Nordisk has moved quickly to file for approval of a higher-dose version of obesity drug Wegovy as it fends off stiff competition from Eli Lilly.

News

MHRA's chief safety officer, Dr Alison Cave

UK probes link between GLP-1 drugs and pancreatitis

The UK is studying cases of pancreatitis in people taking GLP-1 drugs for weight loss or type 2 diabetes to see if genetics may make them vulnerable.

Novo Nordisk claims first GLP-1 approval in MASH

Novo Nordisk weakens again on interim results readout

Noom expands its GLP-1 range with 'microdose' package

Novo Nordisk slumps as it cuts sales forecast, names new CEO

Novo Nordisk files high-dose Wegovy in EU

UK probes link between GLP-1 drugs and pancreatitis

Novo sues Lilly over 'misleading' GLP-1 ad campaigning

Discover a new era of healthcare panel engagement: Grounded ...

Wegovy

Editor's Picks